The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

injection site rash and injection site dermatitis were reported in the COPD trials. Adverse events more commonly observed with Dupixent (≥5%) compared to placebo in either COPD trial were back ...

During the 52-week treatment period, Dupixent led to fewer flare-ups, better lung function and quality of life, and reduced respiratory symptoms compared with a placebo. The most common side effects ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

12, 2024 /CNW/ - Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT ® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for certain adults with poorly controlled chronic obstructive pulmonary disease (COPD).

injection site pain, and headache. EoE is a chronic, progressive disease that can severely impact a child's ability to eat and thrive, with symptoms often mistaken for other conditions. Dupixent ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...